China Securities Network News (Reporter Wei Zhaoyu) On December 2, the wholly foreign-owned public offering of Neuberger Berman announced that the equity product Neuberger Berman China Medical and Health ** will be officially launched on December 6, and the sale period will end on December 22. It is reported that this product is also the first thematic equity product of Neuberger Berman**.
According to public information, the product is an initiator**, the amount of initiation funds subscribed is not less than 10 million yuan, and the holding period of the ** share of initiation funds subscription is not less than 3 years.
It is reported that the product is intended to be led by the first manager Li Tao. **According to the prospectus, Tao Li is a Ph.D. in genetics from Shanghai Jiao Tong University. He joined Neuberger Berman Management (China) in February 2023 and is currently the assistant manager of the investment department, with more than 11 years of industry investment research experience, including industry researcher at Everbright Prudential, industry analyst at China Universal Asset Management, industry analyst at IFC, research director and investment manager at Shanghai Zhijun Asset Management, researcher and investment manager at Shanghai Shiva Private Equity Management Center.